search
Back to results

Binge Drinking of Alcohol Mixed With Energy Drinks (ENERGYBINGE)

Primary Purpose

Healthy, Alcohol Drinking

Status
Unknown status
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Alcohol and Energy Drink (AmED)
Alcohol and Energy drink Placebo
Alcohol placebo and Energy drink
Alcohol placebo and energy drink placebo
Sponsored by
Fundació Institut Germans Trias i Pujol
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Healthy focused on measuring alcohol binge drinking, alcohol, energy drinks, pharmacokinetics, caffeine, gender

Eligibility Criteria

18 Years - 40 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Males and females between 18-40 years old, weight between 50 and 100 kg and BMI (BMI=weight/height²) between 20-28 kg/m². Lower or higher BMIs will be allowed, if the researchers considered that do not suppose a risk to the subjects and do not interfere with the objectives of the study.
  2. Recreational alcohol consumption in form of occasional binge-drinking (≥1 episode / month) and at least consumption of 1 unit (10 g, "standard" drink - one alcoholic drink equivalent) per day or its equivalent over the whole week [7 units, 70 g)]) and having experienced drunkenness several times
  3. Regular consumption of beverages containing methylxanthines at least 7 per week (coffee, tea, chocolate, cola soda, energy drinks). Consumption of energy drinks at least once.
  4. Understand and accept the study's procedures and sign an informed consent form.
  5. No evidence of somatic or psychiatric disorders as per past medical history and physical examination.
  6. The ECG and general blood and urine laboratory tests performed before the study should be within normal ranges. Minor or occasional changes from normal ranges are accepted if, in the investigator's opinion, considering the current state of the art, they are not clinically significant, are not life-threatening for the subjects and do not interfere with the product assessment. These changes and their non-relevance will be justified in writing specifically.

Exclusion Criteria:

  1. Not fill the inclusion criteria.
  2. Pathological history or evidence of a preexisting condition (including gastrointestinal, liver, or kidney disorders) that may alter the absorption, distribution, metabolism or excretion of drugs or symptoms suggestive of drug-induced gastrointestinal irritation.
  3. Present history of a substance use disorder according to Diagnostic and Statistical Manual for Mental Disorders (DSM-V), except for nicotine. Past history of mild substance use disorder (corresponding to substance abuse according to DSM-IV) could be included.
  4. Previous or actual psychiatric disorders, alcoholism, abuse of prescription drugs or illegal substances or regular consumption of psychoactive drugs.
  5. Having donated blood or having participated in this same study in the preceding 8 weeks, or having participated in any clinical trial with drugs in the preceding 12 weeks
  6. Having had any somatic disease or having undergone major surgery in the 3 months prior to inclusion in the trial.
  7. Individuals intolerant or having experienced a severe adverse reaction to alcohol or energy drinks. Asian subjects with no intolerance or no serious adverse reactions to alcohol could be included.
  8. Having regularly taken medication in the month before the trial, except for vitamins, herb-based remedies, dietary supplements that if, according to the Principal Investigator or his appointed collaborators' opinion, they pose no threat to the subjects and they won't interfere with the study's objectives. Single doses of symptomatic drugs taken during the week before the experimental session will not constitute an exclusion criterion if it can be assumed that it has been completely eliminated on the day of the experimental session.
  9. Smokers of >5 cigarettes/day
  10. Consumption of >20 g/day of alcohol (females) or of >40 g/day (males)
  11. Daily consumption of more than 5 coffees, teas, cola drinks or other stimulant or xanthine-containing beverages in the 3 months prior to inclusion in the study.
  12. Subjects unable to understand the nature, consequences of the study and the procedures requested to be followed.
  13. Subjects with positive serology to Hepatitis B, C or HIV.
  14. Pregnant, breastfeeding women and those using hormonal contraception,. Those not using an effective contraceptive (i.e. abstinence, intrauterine devices, barrier methods or partner vasectomy).
  15. Women with amenorrhea or suffering severe premenstrual syndrome.

Sites / Locations

  • Hospital Universitari Germans Trias i Pujol-Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP)Recruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

Alcohol and Energy Drink (AmED)

Alcohol and Energy drink Placebo

Alcohol placebo and Energy drink

Alcohol placebo and Energy drink placebo

Arm Description

The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total). Women: Ethanol 172 ml (55 g) + ED 589 ml Men: Ethanol 219 ml (70 g) + ED 750 ml

The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total). Women: Ethanol 172 mL (55 g) + placebo ED (a non-caffeinated soft drink) 589 mL Men: Ethanol 219 mL(70 g) + placebo ED 750 mL (a non-caffeinated soft drink)

The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total). Women: Ethanol placebo (water) 172 mL + ED 589 mL Men: Ethanol placebo (water) 219 mL + ED 750 mL

The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total). Women: Ethanol placebo (water) 172 mL+ placebo ED (a non-caffeinated soft drink) 589 mL Men: Ethanol placebo (water) 219 mL + placebo ED (a non-caffeinated soft drinks) 750 mL

Outcomes

Primary Outcome Measures

Change in subjective effects measured with Biphasic alcohol effects scale (BAES)
Subjective effects of alcohol will be measured using Biphasic alcohol effects scale (0-70 points). Higher scores mean worse outcome. Obtained baseline and 1, 1.30, 2, 3, 4, 6 and 8-h after administration.
Change in psychomotor vigilance task (PVT)
Test will be performed using a specific software. Mean latency will be measured. Obtained baseline and 1.30, 4 and 6-h after administration.

Secondary Outcome Measures

Area under the concentration-time curve (AUC 0-8h) of ethanol blood concentrations
Calculation of AUC of ethanol blood concentrations. Obtained baseline and 0.30h , 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.
Area under the concentration-time curve (AUC 0-8h) of ethanol breath concentrations
Obtained baseline and 0.15, 0.30 , 0.45, 1, 1.15,1.30, 1.45, 2, 2.15, 2.30, 3, 4, 6 and 8-h after administration.
Area under the concentration-time curve (AUC 0-8h) of caffeine blood concentrations
Calculation of AUC of caffeine concentrations obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.
Maximum concentration (Cmax) of ethanol in blood
Maximum concentration (Cmax) of ethanol in blood
Maximum concentration (Cmax) of caffeine in plasma
Maximum concentration (Cmax) of caffeine in plasma
Time to reach maximum concentration (tmax) of ethanol in blood
Time to reach maximum concentration (tmax) of ethanol in blood
Time to reach maximum concentration (tmax) of ethanol in breath air
Time to reach maximum concentration (tmax) of ethanol in breath air
Time to reach maximum concentration (tmax) of caffeine in plasma
Time to reach maximum concentration (tmax) of caffeine in plasma
Area under the concentration-time curve (AUC 0-8h) of taurine plasma concentrations
Calculation of AUC of taurine concentrations obtained baseline and 0.30h , 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration
Maximum concentration (Cmax) of taurine plasma concentrations
Maximum concentration (Cmax) of taurine plasma concentrations
Time to reach maximum concentration (tmax) of taurine plasma concentrations
Time to reach maximum concentration (tmax) of taurine plasma concentrations
Change in drunkenness feeling
Drunkenness will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.
Change in dizziness feeling
Dizziness will be measured using a visual analog scale (0-100 mm).Higher scores mean worse outcome. Obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.
Change in drowsiness feeling
Drowsiness will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.
Change in palpitations reported by the participant
Palpitations will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.
Change in anxiety feeling
Anxiety will be measured using a visual analog scale (0-100 mm).Higher scores mean worse outcome. Obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.
Change in headache
Headache will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.
Change in ability and predisposition to drive in certain situations
Will be measured using a visual analog scale (0-100 mm).Higher scores mean worse outcome. Obtained baseline and 1.30, 4, 6 and 8-h after administration.
Desire to keep drinking
Will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained at the end of beverage administration. Only one measure at 1.30 hours.
Change in subjective effects measured with Addiction Research Center Inventory (ARCI)
Obtained baseline and 1, 1.45, 4, 6 and 8-h after administration.
Change in blood pressure
Systolic and diastolic blood pressure (mmHg) will be measured obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.
Change in heart rate
Heart rate (beats/min) will be measured obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.
Change in oral temperature
Oral temperature (ºC) will be measured obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.
Change in Maddox Wing score (MW)
Maddox wing is a device for the measurement of diopters of horizontal heterophoria. From 22 (exophoria) to 15 (esophoria). Higher scores mean worse outcome.Obtained baseline and 1.30, 4 and 6-h after administration.
Beverage identification
Beverage identification questionnaire.There is an option to select each treatment condition. Only measured at 8h after administration
Change in tracking test performance
Test will be performed using a computer program. Total time outside the road and number of errors will be measured. Obtained baseline and 1.30, 4 and 6-h after administration.

Full Information

First Posted
October 30, 2020
Last Updated
November 5, 2020
Sponsor
Fundació Institut Germans Trias i Pujol
Collaborators
Germans Trias i Pujol Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04616859
Brief Title
Binge Drinking of Alcohol Mixed With Energy Drinks
Acronym
ENERGYBINGE
Official Title
Combination of Alcohol and Energy Drinks in a Binge Drinking Pattern: Acute Effects and Gender Differences
Study Type
Interventional

2. Study Status

Record Verification Date
November 2020
Overall Recruitment Status
Unknown status
Study Start Date
October 8, 2020 (Actual)
Primary Completion Date
December 2021 (Anticipated)
Study Completion Date
December 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fundació Institut Germans Trias i Pujol
Collaborators
Germans Trias i Pujol Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the study is to assess the relevance of gender in the acute effects (subjective, physiological and driving-related skills) observed after controlled administration of alcohol in a binge-drinking pattern mixed with energy drinks (AmED)
Detailed Description
Consumption of alcohol mixed with energy drinks (AmED) has increased mainly among young people. Energy drinks (ED) are usually combined with alcohol with the intention of counteracting its effects. However, most studies have not shown a reduction in drunkenness and consumption is related with engagement of risk-taking behaviours like driving under alcohol effects. It is already known that alcohol concentrations and effects are higher in women than in men even after adjusting dose by weight. The relevance of gender in the acute effects of alcohol associated with ED consumed in a binge-drinking pattern has been poorly studied. A randomized clinical trial will be conducted in healthy volunteers (1:1) and four treatment conditions will be administered: alcohol+ED, alcohol+placebo of ED, placebo of alcohol+ED and placebo of alcohol+placebo of ED. Subjective and physiological effects, driving related skills, and alcohol and caffeine concentrations will be measured along an 8-hours period. A pilot study has been conducted with the first 6 volunteers to select the alcohol doses. In the definitive study 70 g of alcohol in men and 55 g in women will be used.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy, Alcohol Drinking
Keywords
alcohol binge drinking, alcohol, energy drinks, pharmacokinetics, caffeine, gender

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Masking Description
Double-blind
Allocation
Randomized
Enrollment
32 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Alcohol and Energy Drink (AmED)
Arm Type
Experimental
Arm Description
The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total). Women: Ethanol 172 ml (55 g) + ED 589 ml Men: Ethanol 219 ml (70 g) + ED 750 ml
Arm Title
Alcohol and Energy drink Placebo
Arm Type
Active Comparator
Arm Description
The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total). Women: Ethanol 172 mL (55 g) + placebo ED (a non-caffeinated soft drink) 589 mL Men: Ethanol 219 mL(70 g) + placebo ED 750 mL (a non-caffeinated soft drink)
Arm Title
Alcohol placebo and Energy drink
Arm Type
Active Comparator
Arm Description
The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total). Women: Ethanol placebo (water) 172 mL + ED 589 mL Men: Ethanol placebo (water) 219 mL + ED 750 mL
Arm Title
Alcohol placebo and Energy drink placebo
Arm Type
Placebo Comparator
Arm Description
The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total). Women: Ethanol placebo (water) 172 mL+ placebo ED (a non-caffeinated soft drink) 589 mL Men: Ethanol placebo (water) 219 mL + placebo ED (a non-caffeinated soft drinks) 750 mL
Intervention Type
Dietary Supplement
Intervention Name(s)
Alcohol and Energy Drink (AmED)
Intervention Description
Multiple oral dose of alcohol mixed with ED
Intervention Type
Dietary Supplement
Intervention Name(s)
Alcohol and Energy drink Placebo
Intervention Description
Multiple oral dose of alcohol mixed with ED placebo (soft drink)
Intervention Type
Dietary Supplement
Intervention Name(s)
Alcohol placebo and Energy drink
Intervention Description
Multiple oral dose of alcohol placebo (water) mixed with ED
Intervention Type
Dietary Supplement
Intervention Name(s)
Alcohol placebo and energy drink placebo
Intervention Description
Multiple oral dose of alcohol placebo (water) mixed with ED placebo (soft drink)
Primary Outcome Measure Information:
Title
Change in subjective effects measured with Biphasic alcohol effects scale (BAES)
Description
Subjective effects of alcohol will be measured using Biphasic alcohol effects scale (0-70 points). Higher scores mean worse outcome. Obtained baseline and 1, 1.30, 2, 3, 4, 6 and 8-h after administration.
Time Frame
From baseline to 8 hours after administration
Title
Change in psychomotor vigilance task (PVT)
Description
Test will be performed using a specific software. Mean latency will be measured. Obtained baseline and 1.30, 4 and 6-h after administration.
Time Frame
From baseline to 6 hours after administration
Secondary Outcome Measure Information:
Title
Area under the concentration-time curve (AUC 0-8h) of ethanol blood concentrations
Description
Calculation of AUC of ethanol blood concentrations. Obtained baseline and 0.30h , 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.
Time Frame
From baseline to 8 hours after administration
Title
Area under the concentration-time curve (AUC 0-8h) of ethanol breath concentrations
Description
Obtained baseline and 0.15, 0.30 , 0.45, 1, 1.15,1.30, 1.45, 2, 2.15, 2.30, 3, 4, 6 and 8-h after administration.
Time Frame
From baseline to 8 hours after administration
Title
Area under the concentration-time curve (AUC 0-8h) of caffeine blood concentrations
Description
Calculation of AUC of caffeine concentrations obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.
Time Frame
From baseline to 8 hours after administration
Title
Maximum concentration (Cmax) of ethanol in blood
Description
Maximum concentration (Cmax) of ethanol in blood
Time Frame
From baseline to 8 hours after administration
Title
Maximum concentration (Cmax) of caffeine in plasma
Description
Maximum concentration (Cmax) of caffeine in plasma
Time Frame
From baseline to 8 hours after administration
Title
Time to reach maximum concentration (tmax) of ethanol in blood
Description
Time to reach maximum concentration (tmax) of ethanol in blood
Time Frame
From baseline to 8 hours after administration
Title
Time to reach maximum concentration (tmax) of ethanol in breath air
Description
Time to reach maximum concentration (tmax) of ethanol in breath air
Time Frame
From baseline to 8 hours after administration
Title
Time to reach maximum concentration (tmax) of caffeine in plasma
Description
Time to reach maximum concentration (tmax) of caffeine in plasma
Time Frame
From baseline to 8 hours after administration
Title
Area under the concentration-time curve (AUC 0-8h) of taurine plasma concentrations
Description
Calculation of AUC of taurine concentrations obtained baseline and 0.30h , 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration
Time Frame
From baseline to 8 hours after administration
Title
Maximum concentration (Cmax) of taurine plasma concentrations
Description
Maximum concentration (Cmax) of taurine plasma concentrations
Time Frame
From baseline to 8 hours after administration
Title
Time to reach maximum concentration (tmax) of taurine plasma concentrations
Description
Time to reach maximum concentration (tmax) of taurine plasma concentrations
Time Frame
From baseline to 8 hours after administration
Title
Change in drunkenness feeling
Description
Drunkenness will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.
Time Frame
From baseline to 8 hours after administration
Title
Change in dizziness feeling
Description
Dizziness will be measured using a visual analog scale (0-100 mm).Higher scores mean worse outcome. Obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.
Time Frame
From baseline to 8 hours after administration
Title
Change in drowsiness feeling
Description
Drowsiness will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.
Time Frame
From baseline to 8 hours after administration
Title
Change in palpitations reported by the participant
Description
Palpitations will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.
Time Frame
From baseline to 8 hours after administration
Title
Change in anxiety feeling
Description
Anxiety will be measured using a visual analog scale (0-100 mm).Higher scores mean worse outcome. Obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.
Time Frame
From baseline to 8 hours after administration
Title
Change in headache
Description
Headache will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.
Time Frame
From baseline to 8 hours after administration
Title
Change in ability and predisposition to drive in certain situations
Description
Will be measured using a visual analog scale (0-100 mm).Higher scores mean worse outcome. Obtained baseline and 1.30, 4, 6 and 8-h after administration.
Time Frame
From baseline to 8 hours after administration
Title
Desire to keep drinking
Description
Will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained at the end of beverage administration. Only one measure at 1.30 hours.
Time Frame
At 1.30 hours
Title
Change in subjective effects measured with Addiction Research Center Inventory (ARCI)
Description
Obtained baseline and 1, 1.45, 4, 6 and 8-h after administration.
Time Frame
From baseline to 8 hours after administration
Title
Change in blood pressure
Description
Systolic and diastolic blood pressure (mmHg) will be measured obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.
Time Frame
From baseline to 8 hours after administration
Title
Change in heart rate
Description
Heart rate (beats/min) will be measured obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.
Time Frame
From baseline to 8 hours after administration
Title
Change in oral temperature
Description
Oral temperature (ºC) will be measured obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.
Time Frame
From baseline to 8 hours after administration
Title
Change in Maddox Wing score (MW)
Description
Maddox wing is a device for the measurement of diopters of horizontal heterophoria. From 22 (exophoria) to 15 (esophoria). Higher scores mean worse outcome.Obtained baseline and 1.30, 4 and 6-h after administration.
Time Frame
From baseline to 6 hours after administration
Title
Beverage identification
Description
Beverage identification questionnaire.There is an option to select each treatment condition. Only measured at 8h after administration
Time Frame
8 hours after administration
Title
Change in tracking test performance
Description
Test will be performed using a computer program. Total time outside the road and number of errors will be measured. Obtained baseline and 1.30, 4 and 6-h after administration.
Time Frame
From baseline to 6 hours after administration

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Males and females between 18-40 years old, weight between 50 and 100 kg and BMI (BMI=weight/height²) between 20-28 kg/m². Lower or higher BMIs will be allowed, if the researchers considered that do not suppose a risk to the subjects and do not interfere with the objectives of the study. Recreational alcohol consumption in form of occasional binge-drinking (≥1 episode / month) and at least consumption of 1 unit (10 g, "standard" drink - one alcoholic drink equivalent) per day or its equivalent over the whole week [7 units, 70 g)]) and having experienced drunkenness several times Regular consumption of beverages containing methylxanthines at least 7 per week (coffee, tea, chocolate, cola soda, energy drinks). Consumption of energy drinks at least once. Understand and accept the study's procedures and sign an informed consent form. No evidence of somatic or psychiatric disorders as per past medical history and physical examination. The ECG and general blood and urine laboratory tests performed before the study should be within normal ranges. Minor or occasional changes from normal ranges are accepted if, in the investigator's opinion, considering the current state of the art, they are not clinically significant, are not life-threatening for the subjects and do not interfere with the product assessment. These changes and their non-relevance will be justified in writing specifically. Exclusion Criteria: Not fill the inclusion criteria. Pathological history or evidence of a preexisting condition (including gastrointestinal, liver, or kidney disorders) that may alter the absorption, distribution, metabolism or excretion of drugs or symptoms suggestive of drug-induced gastrointestinal irritation. Present history of a substance use disorder according to Diagnostic and Statistical Manual for Mental Disorders (DSM-V), except for nicotine. Past history of mild substance use disorder (corresponding to substance abuse according to DSM-IV) could be included. Previous or actual psychiatric disorders, alcoholism, abuse of prescription drugs or illegal substances or regular consumption of psychoactive drugs. Having donated blood or having participated in this same study in the preceding 8 weeks, or having participated in any clinical trial with drugs in the preceding 12 weeks Having had any somatic disease or having undergone major surgery in the 3 months prior to inclusion in the trial. Individuals intolerant or having experienced a severe adverse reaction to alcohol or energy drinks. Asian subjects with no intolerance or no serious adverse reactions to alcohol could be included. Having regularly taken medication in the month before the trial, except for vitamins, herb-based remedies, dietary supplements that if, according to the Principal Investigator or his appointed collaborators' opinion, they pose no threat to the subjects and they won't interfere with the study's objectives. Single doses of symptomatic drugs taken during the week before the experimental session will not constitute an exclusion criterion if it can be assumed that it has been completely eliminated on the day of the experimental session. Smokers of >5 cigarettes/day Consumption of >20 g/day of alcohol (females) or of >40 g/day (males) Daily consumption of more than 5 coffees, teas, cola drinks or other stimulant or xanthine-containing beverages in the 3 months prior to inclusion in the study. Subjects unable to understand the nature, consequences of the study and the procedures requested to be followed. Subjects with positive serology to Hepatitis B, C or HIV. Pregnant, breastfeeding women and those using hormonal contraception,. Those not using an effective contraceptive (i.e. abstinence, intrauterine devices, barrier methods or partner vasectomy). Women with amenorrhea or suffering severe premenstrual syndrome.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Clara Pérez-Mañá, MD,PhD
Phone
+34 93 497 88 65
Email
cperezm.mn.ics@gencat.cat
First Name & Middle Initial & Last Name or Official Title & Degree
Magi Farré, MD, PhD
Phone
+34 93 497 88 65
Email
mfarre.germanstrias@gencat.cat
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clara Pérez-Mañá, MD, PhD
Organizational Affiliation
Hospital Universitari Germans Trias i Pujol-IGTP
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Universitari Germans Trias i Pujol-Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP)
City
Badalona
State/Province
Barcelona
ZIP/Postal Code
08916
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Clara Pérez-Mañá, MD, PhD
Phone
+34 934978865
Email
cperezm.mn.ics@gencat.cat
First Name & Middle Initial & Last Name & Degree
Magi Farré, MD,PhD
Phone
+34 934978865
Email
mfarre.germanstrias@gencat.cat
First Name & Middle Initial & Last Name & Degree
Clara Pérez-Mañá, MD, PhD
First Name & Middle Initial & Last Name & Degree
Magí Farré, MD, PhD
First Name & Middle Initial & Last Name & Degree
Esther Papaseit, MD, PhD
First Name & Middle Initial & Last Name & Degree
Ana Maria Barriocanal, MD, PhD
First Name & Middle Initial & Last Name & Degree
Soraya Martin, RN
First Name & Middle Initial & Last Name & Degree
Alexandra Vila, RN
First Name & Middle Initial & Last Name & Degree
Olga Hladun, MD
First Name & Middle Initial & Last Name & Degree
Ana Pilar Pérez, MD
First Name & Middle Initial & Last Name & Degree
Melani Nuñez, MD
First Name & Middle Initial & Last Name & Degree
Lourdes Poyatos, BS

12. IPD Sharing Statement

Learn more about this trial

Binge Drinking of Alcohol Mixed With Energy Drinks

We'll reach out to this number within 24 hrs